These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24843617)

  • 1. Efficacy and safety of alogliptin added to sulfonylurea in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.
    Seino Y; Hiroi S; Hirayama M; Kaku K
    J Diabetes Investig; 2012 Dec; 3(6):517-25. PubMed ID: 24843617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.
    Kaku K; Itayasu T; Hiroi S; Hirayama M; Seino Y
    Diabetes Obes Metab; 2011 Nov; 13(11):1028-35. PubMed ID: 21682833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Nov; 27 Suppl 3():21-9. PubMed ID: 22106975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of alogliptin added to insulin in Japanese patients with type 2 diabetes: a randomized, double-blind, 12-week, placebo-controlled trial followed by an open-label, long-term extension phase.
    Kaku K; Mori M; Kanoo T; Katou M; Seino Y
    Expert Opin Pharmacother; 2014 Oct; 15(15):2121-30. PubMed ID: 25190226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
    Kim HJ; Jeong IK; Hur KY; Kim SK; Noh JH; Chun SW; Kang ES; Rhee EJ; Choi SH
    Diabetes Metab J; 2022 Sep; 46(5):689-700. PubMed ID: 35295073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial.
    Strojek K; Yoon KH; Hruba V; Sugg J; Langkilde AM; Parikh S
    Diabetes Ther; 2014 Jun; 5(1):267-83. PubMed ID: 24920277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study.
    Seino Y; Fujita T; Hiroi S; Hirayama M; Kaku K
    Curr Med Res Opin; 2011 Sep; 27(9):1781-92. PubMed ID: 21806314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
    Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH; Patel S; Harper R; Toorawa R; Thiemann S; von Eynatten M; Woerle HJ
    Diabetes Obes Metab; 2012 Dec; 14(12):1145-54. PubMed ID: 22974280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
    White JL; Buchanan P; Li J; Frederich R
    BMC Endocr Disord; 2014 Feb; 14():17. PubMed ID: 24565221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Luis Bautista J; Bugos C; Dirnberger G; Atherton T
    Clin Ther; 2003 Jan; 25(1):194-209. PubMed ID: 12637120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
    Handelsman Y; Lauring B; Gantz I; Iredale C; O'Neill EA; Wei Z; Suryawanshi S; Kaufman KD; Engel SS; Lai E
    Curr Med Res Opin; 2017 Oct; 33(10):1861-1868. PubMed ID: 28548024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glimepiride/metformin fixed-dose combination vs metformin uptitration in type 2 diabetic patients inadequately controlled on low-dose metformin monotherapy: A randomized, open label, parallel group, multicenter study in Korea.
    Kim HS; Kim DM; Cha BS; Park TS; Kim KA; Kim DL; Chung CH; Park JH; Jang HC; Choi DS
    J Diabetes Investig; 2014 Nov; 5(6):701-8. PubMed ID: 25422771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Post Hoc Analysis of HbA1c, Hypoglycemia, and Weight Change Outcomes with Alogliptin vs Glipizide in Older Patients with Type 2 Diabetes.
    Bron M; Wilson C; Fleck P
    Diabetes Ther; 2014 Dec; 5(2):521-34. PubMed ID: 25424968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
    McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
    Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.
    DeFronzo RA; Fleck PR; Wilson CA; Mekki Q;
    Diabetes Care; 2008 Dec; 31(12):2315-7. PubMed ID: 18809631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of teneligliptin in combination with pioglitazone in Japanese patients with type 2 diabetes mellitus.
    Kadowaki T; Kondo K
    J Diabetes Investig; 2013 Nov; 4(6):576-84. PubMed ID: 24843712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Hollander P; Hill J; Johnson J; Wei Jiang Z; Golm G; Huyck S; Terra SG; Mancuso JP; Engel SS; Lauring B; Liu J
    Curr Med Res Opin; 2019 Aug; 35(8):1335-1343. PubMed ID: 30760125
    [No Abstract]   [Full Text] [Related]  

  • 19. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy.
    Barnett AH; Charbonnel B; Li J; Donovan M; Fleming D; Iqbal N
    Clin Drug Investig; 2013 Oct; 33(10):707-17. PubMed ID: 23949898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.
    Shimoda S; Iwashita S; Sekigami T; Furukawa N; Matsuo Y; Ichimori S; Goto R; Maeda T; Watanabe E; Kondo T; Matsumura T; Motoshima H; Nishida K; Araki E
    J Diabetes Investig; 2014 May; 5(3):320-6. PubMed ID: 24843781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.